Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
Shukui Qin(81th Hospital of PLA), Chunyi Hao(Peking University), Zhenggang Ren(Ministry of Education of the People's Republic of China), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Baek‐Yeol Ryoo(Asan Medical Center), Yimin Mao(Shaoguan University), Wen Yan Zhong, Xiufeng Liu, Yuxian Bai(Harbin Medical University), Jianfeng Li(First Hospital of China Medical University), Yu Zhou, Zhendong Chen(Anhui Medical University), Xing Ye(Wuhan University), Zhiqiang Meng(Shanghai Medical College of Fudan University), Juxiang Xiao(First Affiliated Hospital of Xi'an Jiaotong University), Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Weijia Fang(Zhejiang Cancer Hospital), Ruocai Xu(Hunan Cancer Hospital), Gwo Fuang Ho(University of Malaya)
Cited by 111
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k